Stockreport

Biomerica Reports Fiscal 2024 Year End Results

Biomerica, Inc.  (BMRA) 
NASDAQ:AMEX Investor Relations: biomerica.com/company/investor.asp
PDF Total Revenue Increases 1% Year-Over-Year – Core Revenue Excluding COVID Tests Climbs 5%, Reflecting Stronger GrowthSignificant Cost Savings Plan Implemented After Year [Read more]